Branimir I. Sikic, M. D.

Publications

• Mechanisms of Resistance to Cabazitaxel
  Duran, G. E., Wang, Y. C., Francisco, E. B., Rose, J. C., Martinez, F. J., & Sikic, B. I. (2015). Mechanisms of Resistance to Cabazitaxel. MOLECULAR CANCER THERAPEUTICS, 14(1), 193-201.
• Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers
  Moisan, F., Francisco, E. B., Brozovic, A., Duran, G. E., Wang, Y. C., & Sikic, B. I. (2014). Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. MOLECULAR ONCOLOGY, 8(7), 1231-1239.
• Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
  Chen, K. G., & Sikic, B. I. (2012). Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance. CLINICAL CANCER RESEARCH, 18(7), 1863-1869.
• Clinical trial designs for testing biomarker-based personalized therapies Lai, T. L., Lavori, P. W., Shih, M.-C. I., & Sikic, B. I. (2012). Clinical trial designs for testing biomarker-based personalized therapies. CLINICAL TRIALS, 9(2), 141-154.
  
• NFKBIA Deletion in Glioblastomas. Bredel, M., Scholtens, D. M., Yadav, A. K., Alvarez, A. A., Renfrow, J. J., & Harsh, G. R. (2011). NFKBIA Deletion in Glioblastomas. NEW ENGLAND JOURNAL OF MEDICINE, 364(7), 627-637.
  
• Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells Spicakova, T., O'Brien, M. M., Duran, G. E., Sweet-Cordero, A., & Sikic, B. I. (2010). Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells. MOLECULAR CANCER THERAPEUTICS, 9(11), 2970-2981.
  
• A Network Model of a Cooperative Genetic Landscape in Brain Tumors Bredel, M., Scholtens, D. M., Harsh, G. R., Bredel, C., Chandler, J. P., & Sikic, B. I. (2009). A Network Model of a Cooperative Genetic Landscape in Brain Tumors. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 302(3), 261-275.
  
• A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer Fischer, Ga., Kuo, T., Ramsey, M., Schwartz, E., Rouse, Rv., & Sikic, B. I. (2008). A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer. CLINICAL CANCER RESEARCH, 14(21), 7074-7079.
  
• Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., & Sikic, B. I. (2007). Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. JOURNAL OF CLINICAL ONCOLOGY, 25(11), 1341-1349.
  
• Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines Wang, Y. C., Juric, D., Francisco, B., Yu, R. X., Duran, G. E., & Sikic, B. I. (2006). Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. GENES CHROMOSOMES & CANCER, 45(4), 365-374.
  
• Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies Cho, C. D., Fisher, G. A., Halsey, J., & Sikic, B. I. (2006). Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. INVESTIGATIONAL NEW DRUGS, 24(2), 117-123.
  
• Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappa B-mediated resistance to O-6-alkylating agents in human glioblastomas Bredel, M., Bredel, C., Juric, D., Duran, G. E., Yu, R. X., & Sikic, B. I. (2006). Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappa B-mediated resistance to O-6-alkylating agents in human glioblastomas. JOURNAL OF CLINICAL ONCOLOGY, 24(2), 274-287.
  
• Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures Juric, D., Sale, S., Hromas, R. A., Yu, R., Wang, Y., & Sikic, B. I. (2005). Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102(49), 17763-17768.
  
• Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line Chen, K. G., Wang, Y. C., Schaner, M. E., Francisco, B., Duran, G. E., & Sikic, B. I. (2005). Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. CANCER RESEARCH, 65(20), 9388-9397.
  
• Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., & Sikic, B. I. (2005). Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. CANCER RESEARCH, 65(19), 8679-8689.
  
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., & Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613-5619.
  
• High-resolution genome-wide mapping of genetic alterations in human glial brain tumors Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., & Sikic, B. I. (2005). High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. CANCER RESEARCH, 65(10), 4088-4096.
  
• Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes Lacayo, N. J., Meshinchi, S., Kinnunen, P., Yu, R., Wang, Y., & Dahl, G. V. (2004). Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. BLOOD, 104(9), 2646-2654.
  
• CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells Chen, G. K., Sale, S., Tan, T., Ermoian, R. P., & Sikic, B. I. (2004). CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. MOLECULAR PHARMACOLOGY, 65(4), 906-916.
  
• Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Lacayo, N. J., Duran, G. E., & Sikic, B. I. (2003). Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Journal of experimental therapeutics & oncology, 3(3), 127-135.
  
• Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma Chen, G. K., Lacayo, N. J., Duran, G. E., Wang, Y., Bangs, C. D., & Sikic, B. I. (2002). Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. GENES CHROMOSOMES & CANCER, 34(4), 372-383.
  
• MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells Chen, G. K., Duran, G. E., Mangili, A., Beketic-Oreskovic, L., & Sikic, B. (2000). MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. BRITISH JOURNAL OF CANCER, 83(7), 892-898.
  
• Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335) Chen, G. K., Lacayo, N. J., Duran, G. E., Cohen, D., & Sikic, B. I. (2000). Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335). MOLECULAR PHARMACOLOGY, 57(4), 769-777.
  
• Modulation of multidrug resistance: A paradigm for translational clinical research Sikic, B. I. (1999). Modulation of multidrug resistance: A paradigm for translational clinical research. ONCOLOGY-NEW YORK, 13(5A), 183-187.
  
• Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., BEKETICORESKOVIC, L., & Chen, G. (1997). Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 40, S13-S19.
  
• Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins Chen, G., Duran, G. E., Steger, K. A., Lacayo, N. J., Jaffrezou, J. P., & Sikic, B. I. (1997). Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. JOURNAL OF BIOLOGICAL CHEMISTRY, 272(9), 5974-5982.
  
• Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol) Dumontet, C., Duran, G. E., Steger, K. A., BEKETICORESKOVIC, L., & Sikic, B. I. (1996). Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). CANCER RESEARCH, 56(5), 1091-1097.
  
• DECREASED MUTATION-RATE FOR CELLULAR-RESISTANCE TO DOXORUBICIN AND SUPPRESSION OF MDR1 GENE ACTIVATION BY THE CYCLOSPORINE PSC-833 BEKETICORESKOVIC, L., Duran, G. E., Chen, G., Dumontet, C., & Sikic, B. I. (1995). DECREASED MUTATION-RATE FOR CELLULAR-RESISTANCE TO DOXORUBICIN AND SUPPRESSION OF MDR1 GENE ACTIVATION BY THE CYCLOSPORINE PSC-833. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 87(21), 1593-1602.
  
• The reversal of multidrug resistance. Fisher, G. A., Lum, B. L., & Sikic, B. I. (1995). The reversal of multidrug resistance. Cancer treatment and research, 78, 45-70.
  
• PREVALENCE OF MULTIDRUG-RESISTANCE RELATED TO ACTIVATION OF THE MDR1 GENE IN HUMAN SARCOMA MUTANTS DERIVED BY SINGLE-STEP DOXORUBICIN SELECTION Chen, G., Jaffrezou, J. P., Fleming, W. H., Duran, G. E., & Sikic, B. I. (1994). PREVALENCE OF MULTIDRUG-RESISTANCE RELATED TO ACTIVATION OF THE MDR1 GENE IN HUMAN SARCOMA MUTANTS DERIVED BY SINGLE-STEP DOXORUBICIN SELECTION. CANCER RESEARCH, 54(18), 4980-4987.
  
• MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ANALYSIS Jaffrezou, J. P., Chen, G., Duran, G. E., Kuhl, J. S., & Sikic, B. I. (1994). MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ANALYSIS. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 86(15), 1152-1158.
  
• PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE Bartlett, N. L., Lum, B. L., Fisher, G. A., BROPHY, N. A., EHSAN, M. N., & Sikic, B. I. (1994). PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 12(4), 835-842.
  
• MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD Sikic, B. I. (1993). MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD. JOURNAL OF CLINICAL ONCOLOGY, 11(9), 1629-1635.
  
• PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE Yahanda, A. M., ADLER, K. M., Fisher, G. A., BROPHY, N. A., Halsey, J., & Sikic, B. I. (1992). PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 10(10), 1624-1634.
  
• ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS BY CYCLOSPORINE IN A PHASE-I TRIAL TO MODULATE MULTIDRUG RESISTANCE Lum, B. L., Kaubisch, S., Yahanda, A. M., ADLER, K. M., JEW, L., & Sikic, B. I. (1992). ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS BY CYCLOSPORINE IN A PHASE-I TRIAL TO MODULATE MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 10(10), 1635-1642.
  
• MULTIDRUG RESISTANCE (MDR1) GENE-EXPRESSION IN ADULT ACUTE LEUKEMIAS - CORRELATIONS WITH TREATMENT OUTCOME AND INVITRO DRUG SENSITIVITY Marie, J. P., Zittoun, R., & Sikic, B. I. (1991). MULTIDRUG RESISTANCE (MDR1) GENE-EXPRESSION IN ADULT ACUTE LEUKEMIAS - CORRELATIONS WITH TREATMENT OUTCOME AND INVITRO DRUG SENSITIVITY. BLOOD, 78(3), 586-592.
  
• MULTIDRUG (PLEIOTROPIC) RESISTANCE IN DOXORUBICIN-SELECTED VARIANTS OF THE HUMAN SARCOMA CELL-LINE MES-SA Harker, W. G., & Sikic, B. I. (1985). MULTIDRUG (PLEIOTROPIC) RESISTANCE IN DOXORUBICIN-SELECTED VARIANTS OF THE HUMAN SARCOMA CELL-LINE MES-SA. CANCER RESEARCH, 45(9), 4091-4096.
  
• DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ANALOG Sikic, B. I., EHSAN, M. N., Harker, W. G., FRIEND, N. F., Brown, B. W., & ACTON, E. M. (1985). DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ANALOG. SCIENCE, 228(4707), 1544-1546.
  
• DEVELOPMENT AND CHARACTERIZATION OF A HUMAN SARCOMA CELL-LINE, MES-SA, SENSITIVE TO MULTIPLE-DRUGS Harker, W. G., MacKintosh, F. R., & Sikic, B. I. (1983). DEVELOPMENT AND CHARACTERIZATION OF A HUMAN SARCOMA CELL-LINE, MES-SA, SENSITIVE TO MULTIPLE-DRUGS. CANCER RESEARCH, 43(10), 4943-4950.
  
• IMPROVED THERAPEUTIC INDEX OF BLEOMYCIN WHEN ADMINISTERED BY CONTINUOUS INFUSION IN MICE Sikic, B. I., Collins, J. M., Mimnaugh, E. G., & Gram, T. E. (1978). IMPROVED THERAPEUTIC INDEX OF BLEOMYCIN WHEN ADMINISTERED BY CONTINUOUS INFUSION IN MICE. CANCER TREATMENT REPORTS, 62(12), 2011-2017.
  
• QUANTIFICATION OF BLEOMYCIN PULMONARY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT AND MORPHOMETRIC HISTOPATHOLOGY Sikic, B. I., Young, D. M., Mimnaugh, E. G., & Gram, T. E. (1978). QUANTIFICATION OF BLEOMYCIN PULMONARY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT AND MORPHOMETRIC HISTOPATHOLOGY. CANCER RESEARCH, 38(3), 787-792.
  
• Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., & Marshall, J. L. (2012). Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 30(6), 2364-2370.
  
• A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer Cabebe, E. C., Fisher, G. A., & Sikic, B. I. (2012). A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 30(3), 1082-1087.
  
• Significance of MicroRNAs in determining taxane resistance in ovarian cancer Sultan, A., Kiet, T., Chan, J., Wang, Y., Duran, G., & Sikic, B. (2012). Significance of MicroRNAs in determining taxane resistance in ovarian cancer. GYNECOLOGIC ONCOLOGY, 125, S131-S131.
  
• Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., & Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971-977.
  
• Integrated genomic analyses of ovarian carcinoma Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D. W., & Thomson, E. (2011). Integrated genomic analyses of ovarian carcinoma. NATURE, 474(7353), 609-615.
  
• Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group O'Brien, M. M., Lacayo, N. J., Lum, B. L., Kshirsagar, S., Buck, S., & Dahl, G. V. (2010). Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group. PEDIATRIC BLOOD & CANCER, 54(5), 694-702.
  
• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., & Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376-381.
  
• A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia Lancet, J. E., Baer, M. R., Duran, G. E., List, A. F., Fielding, R., & Sikic, B. I. (2009). A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. LEUKEMIA RESEARCH, 33(8), 1055-1061.
  
• Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas Yadav, A. K., Renfrow, J. J., Scholtens, D. M., Xie, H., Duran, G. E., & Bredel, M. (2009). Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 302(3), 276-289.
  
• Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia Marcelletti, J. F., Multani, P. S., Lancet, J. E., Baer, M. R., & Sikic, B. I. (2009). Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. LEUKEMIA RESEARCH, 33(6), 769-774.
  
• A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors Rosen, L. S., Galatin, P., Fehling, J. M., Laux, I., Dinolfo, M., & Sikic, B. I. (2008). A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer Cabebe, E. C., Kuo, T., Koong, A., Welton, M., Shelton, A., & Fisher, G. A. (2008). Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer Kuo, T., Cabebe, E. C., Koong, A., NORTON, J. A., Kunz, P. L., & Fisher, G. A. (2008). An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success? Chan, J. K., Ueda, S. M., Sugiyama, V. E., Stave, C. D., Shin, J. Y., & Kapp, D. S. (2008). Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success?. JOURNAL OF CLINICAL ONCOLOGY, 26(9), 1511-1518.
  
• Predictors for success in a phase III trial - an analysis of 315 phase II chemotherapy trials for advanced cancers Ueda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., & Chan, J. K. (2007). Predictors for success in a phase III trial - an analysis of 315 phase II chemotherapy trials for advanced cancers. GYNECOLOGIC ONCOLOGY, 107(2), 362-363.
  
• Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Juric, D., Bredel, C., Sikic, B. I., & Bredel, M. (2007). Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Methods in molecular biology (Clifton, N.J.), 377, 187-202.
  
• Gene expression profiling predicts outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421. Lacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., & Van Houten Dahl, G. (2006). Gene expression profiling predicts outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421. BLOOD, 108(11), 542A-542A.
  
• Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias. Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., & Sikic, B. I. (2006). Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias. BLOOD, 108(11), 520A-520A.
  
• A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the eastern cooperative oncology group Carlson, R. W., O'Neill, A. M., Goldstein, L. J., Sikic, B. I., Abramson, N., & Wood, W. C. (2006). A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the eastern cooperative oncology group. CANCER INVESTIGATION, 24(7), 677-681.
  
• A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM) Sikic, B. I., Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., & Piens, J. R. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM). EJC SUPPLEMENTS, 4(12), 106-107.
  
• A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., & Sikic, B. I. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 131S-131S.
  
• Multidrug resistance and stem cells in acute myeloid leukemia Sikic, B. I. (2006). Multidrug resistance and stem cells in acute myeloid leukemia. CLINICAL CANCER RESEARCH, 12(11), 3231-3232.
  
• Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., & Dahl, G. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. LEUKEMIA, 20(3), 426-432.
  
• Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421 Becton, D., Dahl, G. V., Ravindranath, Y., Chang, M. N., Behm, F. G., & Weinstein, H. (2006). Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. BLOOD, 107(4), 1315-1324.
  
• A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. Wakelee, H., Adjei, A. A., Halsey, J., Lensing, J., Dugay, J., & Sikic, B. I. (2005). A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. CLINICAL CANCER RESEARCH, 11(24), 9029S-9029S.
  
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968-1973.
  
• Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421. Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., & Dahl, G. V. (2005). Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421. BLOOD, 106(11), 667A-667A.
  
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., & Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467-477.
  
• Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors Wakelee, H. A., & Sikic, B. I. (2005). Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors. CLINICAL LUNG CANCER, 7, S6-S12.
  
• A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer Chi, K. N., Chia, S. K., Dixon, R., Newman, M. J., Wacher, V. J., & Gelmon, K. A. (2005). A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(4), 311-315.
  
• A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies Wakelee, H., Adjei, A. A., Keer, H., Halsey, J., Hanson, L., & Sikic, B. I. (2005). A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 227S-227S.
  
• A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S-234S.
  
• Amplification of whole tumor genomes and geneby-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA Bredel, M., Bredel, C., Juric, D., Kim, Y., Vogel, H., & Sikic, B. I. (2005). Amplification of whole tumor genomes and geneby-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. JOURNAL OF MOLECULAR DIAGNOSTICS, 7(2), 171-182.
  
• Osteonectin/SPARC is epigenetically silenced in AML with MLL gene rearrangements and selectively inhibits the growth of MLL rearranged cell lines DiMartino, J. F., Lacayo, N. J., Varadi, M., Ravindranath, Y., Yu, R., & Dahl, G. V. (2004). Osteonectin/SPARC is epigenetically silenced in AML with MLL gene rearrangements and selectively inhibits the growth of MLL rearranged cell lines. BLOOD, 104(11), 314A-314A.
  
• A method for detecting and correcting feature misidentification on expression microarrays Tu, I. P., Schaner, M., Diehn, M., Sikic, B. I., Brown, P. O., & Fero, M. J. (2004). A method for detecting and correcting feature misidentification on expression microarrays. BMC GENOMICS, 5.
  
• Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Dumontet, C., Jaffrezou, J.-P., Tsuchiya, E., Duran, G. E., Chen, G., & Sikic, B. I. (2004). Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bulletin du cancer, 91(5), E81-112.
  
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., & Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078-1086.
  
• Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Bredel, M., Bredel, C., & Sikic, B. I. (2004). Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours?. LANCET ONCOLOGY, 5(2), 89-100.
  
• A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma Advani, R., Peethambaram, P., Lum, B. L., Fisher, G. A., Hartmann, L., & Sikic, B. I. (2004). A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. CANCER, 100(2), 321-326.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., & Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S-6103S.
  
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., & Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187-5194.
  
• Gene expression patterns in ovarian carcinomas Schaner, M. E., Ross, D. T., Ciaravino, G., Sorlie, T., Troyanskaya, O., & Sikic, B. I. (2003). Gene expression patterns in ovarian carcinomas. MOLECULAR BIOLOGY OF THE CELL, 14(11), 4376-4386.
  
• Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer Hartman, A. R., Grekowicz, A., Lum, B. L., Carlson, R. W., Schurman, C., & Stockdale, F. E. (2003). Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 82(1), 61-69.
  
• Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis: Emergence of a clear cell signature profile Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., & Longacre, T. (2003). Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis: Emergence of a clear cell signature profile. MODERN PATHOLOGY, 16(1), 181A-181A.
  
• Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis: Emergence of a clear cell signature profile Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., & Longacre, T. (2003). Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis: Emergence of a clear cell signature profile. LABORATORY INVESTIGATION, 83(1), 181A-181A.
  
• Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography Chin, D. L., Lum, B. L., & Sikic, B. I. (2002). Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 779(2), 259-269.
  
• A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., & Sikic, B. I. (2002). A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. EUROPEAN JOURNAL OF CANCER, 38, S63-S63.
  
• A phase I pharmacokinetic study of ONT-093 in combination with paclitaxel in patients with advanced cancer Chi, K. N., Chia, S. K., Sikic, B., Dixon, R., Newman, M., & Gelmon, K. A. (2002). A phase I pharmacokinetic study of ONT-093 in combination with paclitaxel in patients with advanced cancer. EUROPEAN JOURNAL OF CANCER, 38, S156-S156.
  
• Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer Sale, S., Oefner, P. J., & Sikic, B. I. (2002). Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 94(10), 776-777.
  
• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia Lacayo, N. J., Lum, B. L., Becton, D. L., Weinstein, H., Ravindranath, Y., & Dahl, G. V. (2002). Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. LEUKEMIA, 16(5), 920-927.
  
• The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., & Sikic, B. I. (2002). The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(2), P48-P48.
  
• Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers Sale, S., Sung, R., Shen, P. D., Yu, K., Wang, Y., & Sikic, B. I. (2002). Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. MOLECULAR CANCER THERAPEUTICS, 1(3), 215-225.
  
• Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin MILLER, R. A., Woodburn, K. W., Fan, Q., Lee, I., Miles, D., & Magda, D. (2001). Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin. CLINICAL CANCER RESEARCH, 7(10), 3215-3221.
  
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221-1229.
  
• Dominant effector genetics in mammalian cells Xu, X., Leo, C., Jang, Y. J., Chan, E., Padilla, D., & Nolan, G. P. (2001). Dominant effector genetics in mammalian cells. NATURE GENETICS, 27(1), 23-29.
  
• Clinical studies of antisense therapy in cancer Yuen, A. R., & Sikic, B. I. (2000). Clinical studies of antisense therapy in cancer. FRONTIERS IN BIOSCIENCE, 5, D588-D593.
  
• Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia Dahl, G. V., Lacayo, N. J., Brophy, N., Dunussi-Joannopoulos, K., Weinstein, H. J., & Arceci, R. J. (2000). Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 18(9), 1867-1875.
  
• Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin Cufer, T., Pfeifer, M., Vrhovec, I., Frangez, R., Kosec, M., & Sikic, B. I. (2000). Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin. ANTI-CANCER DRUGS, 11(4), 303-309.
  
• Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., & Sikic, B. I. (2000). Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 45(4), 305-311.
  
• Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., & Rowe, J. M. (1999). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). BLOOD, 94(10), 383A-383A.
  
• Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., & Sikic, B. I. (1999). Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. CLINICAL CANCER RESEARCH, 5(11), 3357-3363.
  
• Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death Dumontet, C., & Sikic, B. I. (1999). Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. JOURNAL OF CLINICAL ONCOLOGY, 17(3), 1061-1070.
  
• Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar) Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., & Greenberg, P. L. (1999). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar). BLOOD, 93(3), 787-795.
  
• Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia - An Eastern Cooperative Oncology Group Pilot Study Tallman, M. S., Lee, S., Sikic, B. I., Paietta, E., Wiernik, P. H., & Rowe, J. M. (1999). Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia - An Eastern Cooperative Oncology Group Pilot Study. CANCER, 85(2), 358-367.
  
• Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC) Advani, R., Visani, G., Milligan, D., Saba, H., Tallman, M., & Greenberg, P. (1999). Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 457, 47-56.
  
• New approaches in cancer treatment Sikic, B. I. (1999). New approaches in cancer treatment. ANNALS OF ONCOLOGY, 10, 149-153.
  
• Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells Washington, C. B., Duran, G. E., Man, M. C., Sikic, B. I., & Blaschke, T. F. (1998). Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 19(3), 203-209.
  
• Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits Cufer, T., Vrhovec, I., Pfeifer, M., Skrk, J., Borstnar, S., & Sikic, B. I. (1998). Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 41(6), 517-521.
  
• Pharmacologic approaches to reversing multidrug resistance Sikic, B. I. (1997). Pharmacologic approaches to reversing multidrug resistance. SEMINARS IN HEMATOLOGY, 34(4), 40-47.
  
• Validation of a limited sampling model to determine etoposide area under the curve Lum, B. L., LANE, K. J., Synold, T. W., Goram, A., Charnick, S. B., & Sikic, B. I. (1997). Validation of a limited sampling model to determine etoposide area under the curve. PHARMACOTHERAPY, 17(5), 887-890.
  
• Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine Advani, R., Warnke, R., Sikic, B. I., & Horning, S. (1997). Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. ANNALS OF ONCOLOGY, 8(6), 601-603.
  
• Spontaneous overexpression of the long form of the bcl-X protein in a highly resistant P388 leukaemia Kuhl, J. S., Krajewski, S., Duran, G. E., Reed, J. C., & Sikic, B. I. (1997). Spontaneous overexpression of the long form of the bcl-X protein in a highly resistant P388 leukaemia. BRITISH JOURNAL OF CANCER, 75(2), 268-274.
  
• Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues Duran, G. E., Lau, D. Hm., Lewis, A. D., Kuhl, J. S., Bammler, T. K., & Sikic, B. I. (1996). Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 38(3), 210-216.
  
• Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: Consensus recommendations Beck, W. T., Grogan, T. M., Willman, C. L., CORDONCARDO, C., Parham, D. M., & Weinstein, R. (1996). Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: Consensus recommendations. CANCER RESEARCH, 56(13), 3010-3020.
  
• Pharmacological considerations in the modulation of multidrug resistance Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance. EUROPEAN JOURNAL OF CANCER, 32A(6), 1082-1088.
  
• Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells Luckie, D. B., Krouse, M. E., Law, T. C., Sikic, B. I., & Wine, J. J. (1996). Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 270(4), C1029-C1036.
  
• Neural network (NN) and linear regression limited sampling models (LSM) for etoposide (E) AUC determinations. Lum, B. L., Synold, T. W., Lane, K., Charnick, S. B., & Sikic, B. I. (1996). Neural network (NN) and linear regression limited sampling models (LSM) for etoposide (E) AUC determinations. CLINICAL PHARMACOLOGY & THERAPEUTICS, 59(2), OIA2-OIA2.
  
• Differential expression of tubulin isotypes during the cell cycle Dumontet, C., Duran, G. E., Steger, K. A., Murphy, G. L., Sussman, H. H., & Sikic, B. I. (1996). Differential expression of tubulin isotypes during the cell cycle. CELL MOTILITY AND THE CYTOSKELETON, 35(1), 49-58.
  
• Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic: Response predictions McCauley, D. L., Lum, B. L., & Sikic, B. I. (1996). Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic: Response predictions. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 37(3), 286-288.
  
• GLUTATHIONE-S-TRANSFERASE-PI, GLUTATHIONE-S-TRANSFERASE-ALPHA, GLUTATHIONE-S-TRANSFERASE-MU AND GLUTATHIONE-S-TRANSFERASE-MDR1 MESSENGER-RNA EXPRESSION IN NORMAL LYMPHOCYTES AND CHRONIC LYMPHOCYTIC-LEUKEMIA Marie, J. P., Simonin, G., Legrand, O., Delmer, A., Faussat, A. M., & Zittoun, R. (1995). GLUTATHIONE-S-TRANSFERASE-PI, GLUTATHIONE-S-TRANSFERASE-ALPHA, GLUTATHIONE-S-TRANSFERASE-MU AND GLUTATHIONE-S-TRANSFERASE-MDR1 MESSENGER-RNA EXPRESSION IN NORMAL LYMPHOCYTES AND CHRONIC LYMPHOCYTIC-LEUKEMIA. LEUKEMIA, 9(10), 1742-1747.
  
• CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS Cufer, T., Vrhovec, I., Skrk, J., Pfeifer, M., Pajk, B., & Sikic, B. I. (1995). CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS. ANTI-CANCER DRUGS, 6(4), 615-618.
  
• INHIBITION OF LYSOSOMAL ACID SPHINGOMYELINASE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE Jaffrezou, J. P., Chen, G., Duran, G. E., Muller, C., Bordier, C., & Levade, T. (1995). INHIBITION OF LYSOSOMAL ACID SPHINGOMYELINASE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1266(1), 1-8.
  
• Drug resistance in clinical oncology and hematology. Introduction. Fisher, G. A., & Sikic, B. I. (1995). Drug resistance in clinical oncology and hematology. Introduction. Hematology/oncology clinics of North America, 9(2), xi-xii.
  
• CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE Fisher, G. A., & Sikic, B. I. (1995). CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 363-382.
  
• Novel mechanism of resistance to paclitaxel (Taxol(R)) in human K562 leukemia cells by combined selection with PSC 833 Jaffrezou, J. P., Dumontet, C., Derry, W. B., Duran, G., Chen, G., & Sikic, B. I. (1995). Novel mechanism of resistance to paclitaxel (Taxol(R)) in human K562 leukemia cells by combined selection with PSC 833. ONCOLOGY RESEARCH, 7(10-11), 517-527.
  
• EVIDENCE FOR TRANSCRIPTIONAL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG-RESISTANT LEUKEMIC-CELLS Muller, C., Goubin, F., Ferrandis, E., CORNILSCHARWTZ, I., Bailly, J. D., & Laurent, G. (1995). EVIDENCE FOR TRANSCRIPTIONAL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG-RESISTANT LEUKEMIC-CELLS. MOLECULAR PHARMACOLOGY, 47(1), 51-56.
  
• ANALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER-CELLS BY INTERACTIVE LASER CYTOMETRY Lau, D. Hm., Duran, G. E., & Sikic, B. I. (1994). ANALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER-CELLS BY INTERACTIVE LASER CYTOMETRY. INTERNATIONAL JOURNAL OF ONCOLOGY, 5(6), 1273-1277.
  
• MULTIDRUG-RESISTANCE IN LYMPHOMAS Yuen, A. R., & Sikic, B. I. (1994). MULTIDRUG-RESISTANCE IN LYMPHOMAS. JOURNAL OF CLINICAL ONCOLOGY, 12(11), 2453-2459.
  
• VOLUME-ACTIVATED CHLORIDE CURRENT IS NOT RELATED TO P-GLYCOPROTEIN OVEREXPRESSION Dong, Y. J., Chen, G., Duran, G. E., Kouyama, K., Chao, A. C., & Gardner, P. (1994). VOLUME-ACTIVATED CHLORIDE CURRENT IS NOT RELATED TO P-GLYCOPROTEIN OVEREXPRESSION. CANCER RESEARCH, 54(19), 5029-5032.
  
• METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A DNA STRAND BREAKER TO A DNA CROSS-LINKER Lau, D. Hm., Duran, G. E., Lewis, A. D., & Sikic, B. I. (1994). METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A DNA STRAND BREAKER TO A DNA CROSS-LINKER. BRITISH JOURNAL OF CANCER, 70(1), 79-84.
  
• MDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS - A CRITICAL-EVALUATION BY 4 TECHNIQUES BROPHY, N. A., Marie, J. P., ROJAS, V. A., Warnke, R. A., MCFALL, P. J., & Sikic, B. I. (1994). MDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS - A CRITICAL-EVALUATION BY 4 TECHNIQUES. LEUKEMIA, 8(2), 327-335.
  
• CYCLOSPORINE A AND CYCLOSPORINE SDZ PSC 833 ENHANCE ANTI-CD5 RICIN A-CHAIN IMMUNOTOXINS IN HUMAN LEUKEMIC T-CELLS Jaffrezou, J. P., Sikic, B. I., & Laurent, G. (1994). CYCLOSPORINE A AND CYCLOSPORINE SDZ PSC 833 ENHANCE ANTI-CD5 RICIN A-CHAIN IMMUNOTOXINS IN HUMAN LEUKEMIC T-CELLS. BLOOD, 83(2), 482-489.
  
• Clinical reversal of multidrug resistance. Sikic, B. I., Fisher, G. A., Lum, B. L., BROPHY, N. A., Yahanda, A. M., & Halsey, J. (1994). Clinical reversal of multidrug resistance. Cancer treatment and research, 73, 149-165.
  
• REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY LEYLANDJONES, B., Dalton, W., Fisher, G. A., & Sikic, B. I. (1993). REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY. CANCER, 72(11), 3484-3488.
  
• CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., & Sikic, B. I. (1993). CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS. CANCER, 72(11), 3502-3514.
  
• EFFECTS OF THE METHOXYMORPHOLINO DERIVATIVE OF DOXORUBICIN AND ITS BIOACTIVATED FORM VERSUS DOXORUBICIN ON HUMAN LEUKEMIA AND LYMPHOMA CELL-LINES AND NORMAL BONE-MARROW Kuhl, J. S., Duran, G. E., Chao, N. J., & Sikic, B. I. (1993). EFFECTS OF THE METHOXYMORPHOLINO DERIVATIVE OF DOXORUBICIN AND ITS BIOACTIVATED FORM VERSUS DOXORUBICIN ON HUMAN LEUKEMIA AND LYMPHOMA CELL-LINES AND NORMAL BONE-MARROW. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 33(1), 10-16.
  
• MOLECULAR TARGETS IN ONCOLOGY - IMPLICATIONS OF THE MULTIDRUG RESISTANCE GENE Lum, B. L., Gosland, M. P., Kaubisch, S., & Sikic, B. I. (1993). MOLECULAR TARGETS IN ONCOLOGY - IMPLICATIONS OF THE MULTIDRUG RESISTANCE GENE. PHARMACOTHERAPY, 13(2), 88-109.
  
• THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., & Sikic, B. I. (1993). THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD. ELSEVIER SCIENCE PUBL B V.
  
• CHARACTERIZATION OF COVALENT DNA-BINDING OF MORPHOLINO AND CYANOMORPHOLINO DERIVATIVES OF DOXORUBICIN Lau, D. Hm., Duran, G. E., & Sikic, B. I. (1992). CHARACTERIZATION OF COVALENT DNA-BINDING OF MORPHOLINO AND CYANOMORPHOLINO DERIVATIVES OF DOXORUBICIN. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 84(20), 1587-1592.
  
• USE OF ETOPOSIDE IN COMBINATION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC-CELLS FROM BONE-MARROW IN A MOUSE MODEL Kuhl, J. S., Sikic, B. I., Blume, K. G., & Chao, N. J. (1992). USE OF ETOPOSIDE IN COMBINATION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC-CELLS FROM BONE-MARROW IN A MOUSE MODEL. EXPERIMENTAL HEMATOLOGY, 20(9), 1048-1054.
  
• ROLE OF CYTOCHROME-P-450 FROM THE HUMAN CYP3A GENE FAMILY IN THE POTENTIATION OF MORPHOLINO DOXORUBICIN BY HUMAN LIVER-MICROSOMES Lewis, A. D., Lau, D. Hm., Duran, G. E., Wolf, C. R., & Sikic, B. I. (1992). ROLE OF CYTOCHROME-P-450 FROM THE HUMAN CYP3A GENE FAMILY IN THE POTENTIATION OF MORPHOLINO DOXORUBICIN BY HUMAN LIVER-MICROSOMES. CANCER RESEARCH, 52(16), 4379-4384.
  
• EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-RNA IN A SUBSET OF NORMAL BONE-MARROW CELLS Marie, J. P., BROPHY, N. A., EHSAN, M. N., Aihara, Y., Mohamed, N. A., & Sikic, B. I. (1992). EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-RNA IN A SUBSET OF NORMAL BONE-MARROW CELLS. BRITISH JOURNAL OF HAEMATOLOGY, 81(2), 145-152.
  
• Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. Kühl, J. S., Sikic, B. I., Blume, K. G., & Chao, N. J. (1992). Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. Progress in clinical and biological research, 377, 25-34.
  
• COMBINED CHEMOTHERAPY AND RADIOTHERAPY FOR ADVANCED-STAGE CARCINOMAS OF THE CERVIX Sikic, B. I. (1992). COMBINED CHEMOTHERAPY AND RADIOTHERAPY FOR ADVANCED-STAGE CARCINOMAS OF THE CERVIX. RADIOTHERAPY / CHEMOTHERAPY INTERACTIONS IN CANCER THERAPY, 26, 153-162.
  
• Purging multidrug resistant cells from bone marrow. Chao, N. J., Aihara, M., Kühl, J. S., Sikic, B. I., & Blume, K. G. (1992). Purging multidrug resistant cells from bone marrow. Progress in clinical and biological research, 377, 13-23.
  
• SENSITIZATION OF DRUG-RESISTANT HUMAN OVARIAN-CANCER CELLS TO CYANOMORPHOLINO DOXORUBICIN (MRA-CN) BY MODULATION OF GLUTATHIONE METABOLISM Lewis, A. D., Duran, G. E., Lau, D. Hm., & Sikic, B. I. (1992). SENSITIZATION OF DRUG-RESISTANT HUMAN OVARIAN-CANCER CELLS TO CYANOMORPHOLINO DOXORUBICIN (MRA-CN) BY MODULATION OF GLUTATHIONE METABOLISM. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 22(4), 821-824.
  
• MULTIFACTORIAL MECHANISMS ASSOCIATED WITH BROAD CROSS-RESISTANCE OF OVARIAN-CARCINOMA CELLS SELECTED BY CYANOMORPHOLINO DOXORUBICIN Lau, D. Hm., Lewis, A. D., EHSAN, M. N., & Sikic, B. I. (1991). MULTIFACTORIAL MECHANISMS ASSOCIATED WITH BROAD CROSS-RESISTANCE OF OVARIAN-CARCINOMA CELLS SELECTED BY CYANOMORPHOLINO DOXORUBICIN. CANCER RESEARCH, 51(19), 5181-5187.
  
• LATE CONSOLIDATIVE RADIATION-THERAPY IN THE TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER Carlson, R. W., Sikic, B. I., Gandara, D. R., HENDRICKSON, C. G., WITTLINGER, P. S., & Phillips, T. L. (1991). LATE CONSOLIDATIVE RADIATION-THERAPY IN THE TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER. CANCER, 68(5), 948-958.
  
• ANTICANCER DRUG DISCOVERY Sikic, B. I. (1991). ANTICANCER DRUG DISCOVERY. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 83(11), 738-740.
  
• A COMBINED APPROACH FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC-CELL LINES IN BONE-MARROW USING A MONOCLONAL-ANTIBODY AND CHEMOTHERAPY Aihara, M., Aihara, Y., SCHMIDTWOLF, G., SCHMIDTWOLF, I., Sikic, B. I., & Chao, N. J. (1991). A COMBINED APPROACH FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC-CELL LINES IN BONE-MARROW USING A MONOCLONAL-ANTIBODY AND CHEMOTHERAPY. BLOOD, 77(9), 2079-2084.
  
• CISPLATIN NEPHROTOXICITY - DIETHYLDITHIOCARBAMATE, WR2721, OR JUST WATER - REPLY Jacobs, C., & Sikic, B. I. (1991). CISPLATIN NEPHROTOXICITY - DIETHYLDITHIOCARBAMATE, WR2721, OR JUST WATER - REPLY. JOURNAL OF CLINICAL ONCOLOGY, 9(4), 708-709.
  
• THE USE OF PROBENECID AS A CHEMOPROTECTOR AGAINST CISPLATIN NEPHROTOXICITY Jacobs, C., Kaubisch, S., Halsey, J., Lum, B. L., GOSLAND, M., & Sikic, B. I. (1991). THE USE OF PROBENECID AS A CHEMOPROTECTOR AGAINST CISPLATIN NEPHROTOXICITY. CANCER, 67(6), 1518-1524.
  
• MODULATION OF ETOPOSIDE (VP-16) CYTOTOXICITY BY VERAPAMIL OR CYCLOSPORINE IN MULTIDRUG-RESISTANT HUMAN LEUKEMIC-CELL LINES AND NORMAL BONE-MARROW Chao, N. J., Aihara, M., Blume, K. G., & Sikic, B. I. (1990). MODULATION OF ETOPOSIDE (VP-16) CYTOTOXICITY BY VERAPAMIL OR CYCLOSPORINE IN MULTIDRUG-RESISTANT HUMAN LEUKEMIC-CELL LINES AND NORMAL BONE-MARROW. EXPERIMENTAL HEMATOLOGY, 18(11), 1193-1198.
  
• SUCCESSFUL TREATMENT OF METASTATIC THYMIC CARCINOMA WITH CISPLATIN, VINBLASTINE, BLEOMYCIN, AND ETOPOSIDE CHEMOTHERAPY Carlson, R. W., Dorfman, R. F., & Sikic, B. I. (1990). SUCCESSFUL TREATMENT OF METASTATIC THYMIC CARCINOMA WITH CISPLATIN, VINBLASTINE, BLEOMYCIN, AND ETOPOSIDE CHEMOTHERAPY. CANCER, 66(10), 2092-2094.
  
• ASSESSMENT OF PURGING WITH MULTIDRUG RESISTANCE (MDR) MODULATORS AND VP-16 - RESULTS OF LONG-TERM MARROW CULTURE Aihara, M., Sikic, B. I., Blume, K. G., & Chao, N. J. (1990). ASSESSMENT OF PURGING WITH MULTIDRUG RESISTANCE (MDR) MODULATORS AND VP-16 - RESULTS OF LONG-TERM MARROW CULTURE. EXPERIMENTAL HEMATOLOGY, 18(8), 940-944.
  
• MODIFICATION OF CISPLATIN TOXICITY WITH DIETHYLDITHIOCARBAMATE Berry, J. M., Jacobs, C., Sikic, B., Halsey, J., & Borch, R. F. (1990). MODIFICATION OF CISPLATIN TOXICITY WITH DIETHYLDITHIOCARBAMATE. JOURNAL OF CLINICAL ONCOLOGY, 8(9), 1585-1590.
  
• PARADOXICAL INCREASE IN DNA CROSS-LINKING IN A HUMAN OVARIAN-CARCINOMA CELL-LINE RESISTANT TO CYANOMORPHOLINO DOXORUBICIN Lau, D. Hm., Ross, K. L., & Sikic, B. I. (1990). PARADOXICAL INCREASE IN DNA CROSS-LINKING IN A HUMAN OVARIAN-CARCINOMA CELL-LINE RESISTANT TO CYANOMORPHOLINO DOXORUBICIN. CANCER RESEARCH, 50(13), 4056-4060.
  
• DELIVERY OF A NORMAL INFANT FOLLOWING CISPLATIN, VINBLASTINE, AND BLEOMYCIN (PVB) CHEMOTHERAPY FOR MALIGNANT TERATOMA OF THE OVARY DURING PREGNANCY CHRISTMAN, J. E., Teng, N. Nh., LEBOVIC, G. S., & Sikic, B. I. (1990). DELIVERY OF A NORMAL INFANT FOLLOWING CISPLATIN, VINBLASTINE, AND BLEOMYCIN (PVB) CHEMOTHERAPY FOR MALIGNANT TERATOMA OF THE OVARY DURING PREGNANCY. GYNECOLOGIC ONCOLOGY, 37(2), 292-295.
  
• PRELIMINARY-RESULTS OF CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY IN ADVANCED CERVICAL-CARCINOMA - A PHASE I-II PROSPECTIVE INTERGROUP NCOG-RTOG STUDY John, M., Flam, M., Sikic, B., Rotman, M., Cooper, J., & Phillips, T. (1990). PRELIMINARY-RESULTS OF CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY IN ADVANCED CERVICAL-CARCINOMA - A PHASE I-II PROSPECTIVE INTERGROUP NCOG-RTOG STUDY. GYNECOLOGIC ONCOLOGY, 37(1), 1-5.
  
• REVERSAL BY CEFOPERAZONE OF RESISTANCE TO ETOPOSIDE, DOXORUBICIN, AND VINBLASTINE IN MULTIDRUG RESISTANT HUMAN SARCOMA-CELLS Gosland, M. P., Lum, B. L., & Sikic, B. I. (1989). REVERSAL BY CEFOPERAZONE OF RESISTANCE TO ETOPOSIDE, DOXORUBICIN, AND VINBLASTINE IN MULTIDRUG RESISTANT HUMAN SARCOMA-CELLS. CANCER RESEARCH, 49(24), 6901-6905.
  
• Antitumor antibiotics. Sikic, B. I. (1989). Antitumor antibiotics. Current opinion in oncology, 1(2), 198-202.
  
• DETECTION OF CELL-AFFECTING AGENTS WITH A SILICON BIOSENSOR Parce, J. W., Owicki, J. C., KERCSO, K. M., Sigal, G. B., Wada, H. G., & McConnell, H. M. (1989). DETECTION OF CELL-AFFECTING AGENTS WITH A SILICON BIOSENSOR. SCIENCE, 246(4927), 243-247.
  
• ASSOCIATION OF DNA CROSS-LINKING WITH POTENTIATION OF THE MORPHOLINO DERIVATIVE OF DOXORUBICIN BY HUMAN-LIVER MICROSOMES Lau, D. Hm., Lewis, A. D., & Sikic, B. I. (1989). ASSOCIATION OF DNA CROSS-LINKING WITH POTENTIATION OF THE MORPHOLINO DERIVATIVE OF DOXORUBICIN BY HUMAN-LIVER MICROSOMES. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 81(13), 1034-1038.
  
• DNA CROSS-LINKING AND CYTO-TOXICITY OF THE ALKYLATING CYANOMORPHOLINO DERIVATIVE OF DOXORUBICIN IN MULTIDRUG-RESISTANT CELLS Scudder, S. A., Brown, J. M., & Sikic, B. I. (1988). DNA CROSS-LINKING AND CYTO-TOXICITY OF THE ALKYLATING CYANOMORPHOLINO DERIVATIVE OF DOXORUBICIN IN MULTIDRUG-RESISTANT CELLS. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 80(16), 1294-1298.
  
• CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II Uemura, M., Winant, R. C., Sikic, B. I., & Brandt, A. E. (1988). CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II. CANCER RESEARCH, 48(18), 5325-5334.
  
• ADVANCED EPITHELIAL OVARIAN-CANCER - SALVAGE WHOLE ABDOMINAL IRRADIATION FOR PATIENTS WITH RECURRENT OR PERSISTENT DISEASE AFTER COMBINATION CHEMOTHERAPY SCHRAY, M. F., Martinez, A., HOWES, A. E., Podratz, K. C., Ballon, S. C., & Sikic, B. I. (1988). ADVANCED EPITHELIAL OVARIAN-CANCER - SALVAGE WHOLE ABDOMINAL IRRADIATION FOR PATIENTS WITH RECURRENT OR PERSISTENT DISEASE AFTER COMBINATION CHEMOTHERAPY. JOURNAL OF CLINICAL ONCOLOGY, 6(9), 1433-1439.
  
• ENHANCEMENT OF THE CLINICAL ACTIVITY OF MELPHALAN BY THE HYPOXIC CELL SENSITIZER MISONIDAZOLE Coleman, C. N., Carlson, R. W., Halsey, J., Kohler, M., Gribble, M., & Jacobs, C. (1988). ENHANCEMENT OF THE CLINICAL ACTIVITY OF MELPHALAN BY THE HYPOXIC CELL SENSITIZER MISONIDAZOLE. CANCER RESEARCH, 48(12), 3528-3532.
  
• DOXORUBICIN AND THE ALKYLATING ANTHRACYCLINE 3'-DEAMINO-3'-(3-CYANO-4-MORPHOLINYL) DOXORUBICIN - COMPARATIVE INVITRO POTENCY AGAINST LEUKEMIA AND BONE-MARROW CELLS Beckman, R. A., MCFALL, P. J., Sikic, B. I., & Smith, S. D. (1988). DOXORUBICIN AND THE ALKYLATING ANTHRACYCLINE 3'-DEAMINO-3'-(3-CYANO-4-MORPHOLINYL) DOXORUBICIN - COMPARATIVE INVITRO POTENCY AGAINST LEUKEMIA AND BONE-MARROW CELLS. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 80(5), 361-365.
  
• ANTIBODY-DIRECTED TARGETING OF LIPOSOMES TO HUMAN CELL-LINES - ROLE OF BINDING AND INTERNALIZATION ON GROWTH-INHIBITION Berinstein, N., Matthay, K. K., Papahadjopoulos, D., Levy, R., & Sikic, B. I. (1987). ANTIBODY-DIRECTED TARGETING OF LIPOSOMES TO HUMAN CELL-LINES - ROLE OF BINDING AND INTERNALIZATION ON GROWTH-INHIBITION. CANCER RESEARCH, 47(22), 5954-5959.
  
• A THERAPY PLANNING ARCHITECTURE THAT COMBINES DECISION-THEORY AND ARTIFICIAL-INTELLIGENCE TECHNIQUES Langlotz, C. P., Fagan, L. M., Tu, S. W., Sikic, B. I., & Shortliffe, E. H. (1987). A THERAPY PLANNING ARCHITECTURE THAT COMBINES DECISION-THEORY AND ARTIFICIAL-INTELLIGENCE TECHNIQUES. COMPUTERS AND BIOMEDICAL RESEARCH, 20(3), 279-303.
  
• CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II Brandt, A. E., Winant, R. C., Uemura, M., & Sikic, B. I. (1987). CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 28, 181-181.
  
• RESISTANCE AND CROSS-RESISTANCE STUDIES OF CYANOMORPHOLINO DOXORUBICIN (MRA-CN) Scudder, S. A., EHSAN, M. N., Tan, Y. O., & Sikic, B. I. (1987). RESISTANCE AND CROSS-RESISTANCE STUDIES OF CYANOMORPHOLINO DOXORUBICIN (MRA-CN). PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 28, 295-295.
  
• DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN Yamauchi, T., Raffin, T. A., Yang, P., & Sikic, B. I. (1987). DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 19(4), 282-286.
  
• CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II Brandt, A. E., Winant, R. C., Uemura, M., & Sikic, B. I. (1987). CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II. JOURNAL OF CELLULAR BIOCHEMISTRY, 158-158.
  
• HIGH-DOSE MEGESTROL-ACETATE THERAPY OF OVARIAN-CARCINOMA - A PHASE-II STUDY BY THE NORTHERN CALIFORNIA ONCOLOGY GROUP Sikic, B. I., Scudder, S. A., Ballon, S. C., SORIERO, O. M., CHRISTMAN, J. E., & Evans, T. L. (1986). HIGH-DOSE MEGESTROL-ACETATE THERAPY OF OVARIAN-CARCINOMA - A PHASE-II STUDY BY THE NORTHERN CALIFORNIA ONCOLOGY GROUP. SEMINARS IN ONCOLOGY, 13(4), 26-32.
  
• ADVANCED EPITHELIAL OVARIAN-CANCER - TOXICITY OF WHOLE ABDOMINAL IRRADIATION AFTER OPERATION, COMBINATION CHEMOTHERAPY, AND REOPERATION SCHRAY, M. F., Martinez, A., HOWES, A. E., Ballon, S. C., Podratz, K. C., & Malkasian, G. D. (1986). ADVANCED EPITHELIAL OVARIAN-CANCER - TOXICITY OF WHOLE ABDOMINAL IRRADIATION AFTER OPERATION, COMBINATION CHEMOTHERAPY, AND REOPERATION. GYNECOLOGIC ONCOLOGY, 24(1), 68-80.
  
• VERAPAMIL-MEDIATED SENSITIZATION OF DOXORUBICIN-SELECTED PLEIOTROPIC RESISTANCE IN HUMAN SARCOMA-CELLS - SELECTIVITY FOR DRUGS WHICH PRODUCE DNA SCISSION Harker, W. G., Bauer, D., ETIZ, B. B., Newman, R. A., & Sikic, B. I. (1986). VERAPAMIL-MEDIATED SENSITIZATION OF DOXORUBICIN-SELECTED PLEIOTROPIC RESISTANCE IN HUMAN SARCOMA-CELLS - SELECTIVITY FOR DRUGS WHICH PRODUCE DNA SCISSION. CANCER RESEARCH, 46(5), 2369-2373.
  
• INVITRO SELECTION AND CHARACTERIZATION OF A BLEOMYCIN-RESISTANT SUBLINE OF B-16 MELANOMA ZUCKERMAN, J. E., Raffin, T. A., Brown, J. M., Newman, R. A., ETIZ, B. B., & Sikic, B. I. (1986). INVITRO SELECTION AND CHARACTERIZATION OF A BLEOMYCIN-RESISTANT SUBLINE OF B-16 MELANOMA. CANCER RESEARCH, 46(4), 1748-1753.
  
• NEUROLOGIC DYSFUNCTION IN PATIENTS TREATED FOR SMALL CELL-CARCINOMA OF THE LUNG - A CLINICAL AND RADIOLOGICAL STUDY CHAK, L. Y., ZATZ, L. M., Wasserstein, P., Cox, R. S., KUSHLAN, P. D., & Sikic, B. I. (1986). NEUROLOGIC DYSFUNCTION IN PATIENTS TREATED FOR SMALL CELL-CARCINOMA OF THE LUNG - A CLINICAL AND RADIOLOGICAL STUDY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 12(3), 385-389.
  
• BIOCHEMICAL AND CELLULAR DETERMINANTS OF BLEOMYCIN CYTOTOXICITY Sikic, B. I. (1986). BIOCHEMICAL AND CELLULAR DETERMINANTS OF BLEOMYCIN CYTOTOXICITY. CANCER SURVEYS, 5(1), 81-91.
  
• PRELIMINARY-OBSERVATIONS OF INTRAPERITONEAL CARBOPLATIN PHARMACOKINETICS DURING A PHASE-I STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP DeGregorio, M. W., Lum, B. L., Holleran, W. M., WILBUR, B. J., & Sikic, B. I. (1986). PRELIMINARY-OBSERVATIONS OF INTRAPERITONEAL CARBOPLATIN PHARMACOKINETICS DURING A PHASE-I STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 18(3), 235-238.
  
• BLEOMYCIN, MITOMYCIN, AND CISPLATIN THERAPY FOR ADVANCED SQUAMOUS CARCINOMA OF THE UTERINE CERVIX - A PHASE-II STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP Picozzi, V. J., Sikic, B. I., Carlson, R. W., Koretz, M., & Ballon, S. C. (1985). BLEOMYCIN, MITOMYCIN, AND CISPLATIN THERAPY FOR ADVANCED SQUAMOUS CARCINOMA OF THE UTERINE CERVIX - A PHASE-II STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP. CANCER TREATMENT REPORTS, 69(7-8), 903-905.
  
• ADVANCED EPITHELIAL OVARIAN-CANCER - WHOLE ABDOMINAL IRRADIATION FOR PATIENTS WITH RECURRENT OR PERSISTENT DISEASE FOLLOWING CHEMOTHERAPY Schray, M., Martinez, A., Howes, A., PODRATZ, K., Ballon, S., & MALKASIAN, G. (1985). ADVANCED EPITHELIAL OVARIAN-CANCER - WHOLE ABDOMINAL IRRADIATION FOR PATIENTS WITH RECURRENT OR PERSISTENT DISEASE FOLLOWING CHEMOTHERAPY. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 8(1), 12-13.
  
• CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CARCINOMA Turbow, M. M., Ballon, S. C., Sikic, B. I., & KORETZ, M. M. (1985). CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CARCINOMA. CANCER TREATMENT REPORTS, 69(5), 465-467.
  
• CENTRAL NERVOUS-SYSTEM TOXICITY AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF INTRAVENTRICULARLY ADMINISTERED BLEOMYCIN IN BEAGLES Levin, V. A., Byrd, D., Sikic, B. I., ETIZ, B. B., Campbell, J., & Davis, R. L. (1985). CENTRAL NERVOUS-SYSTEM TOXICITY AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF INTRAVENTRICULARLY ADMINISTERED BLEOMYCIN IN BEAGLES. CANCER RESEARCH, 45(8), 3810-3815.
  
• GASTRIN RELEASING PEPTIDE IS A SELECTIVE MITOGEN FOR SMALL CELL LUNG-CARCINOMA INVITRO Weber, S., ZUCKERMAN, J. E., Bostwick, D. G., Bensch, K. G., Sikic, B. I., & Raffin, T. A. (1985). GASTRIN RELEASING PEPTIDE IS A SELECTIVE MITOGEN FOR SMALL CELL LUNG-CARCINOMA INVITRO. JOURNAL OF CLINICAL INVESTIGATION, 75(1), 306-309.
  
• 2ND-LOOK LAPAROTOMY IN EPITHELIAL OVARIAN-CARCINOMA - PRECISE DEFINITION, SENSITIVITY, AND SPECIFICITY OF THE OPERATIVE PROCEDURE Ballon, S. C., PORTNUFF, J. C., Sikic, B. I., Turbow, M. M., Teng, N. Nh., & SORIERO, O. M. (1984). 2ND-LOOK LAPAROTOMY IN EPITHELIAL OVARIAN-CARCINOMA - PRECISE DEFINITION, SENSITIVITY, AND SPECIFICITY OF THE OPERATIVE PROCEDURE. GYNECOLOGIC ONCOLOGY, 17(2), 154-160.
  
• DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN Yamauchi, T., Raffin, T. A., Weber, S., ZUCKERMAN, J. E., Yang, P., & Sikic, B. I. (1984). DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN. CHEST, 86(2), 311-311.
  
• MULTI-DRUG (PLEIOTROPIC) RESISTANCE SELECTED BY DOXORUBICIN, IN SUBLINES OF THE HUMAN SARCOMA CELL-LINE MES-SA Harker, W. G., Stewart, S. J., & Sikic, B. I. (1984). MULTI-DRUG (PLEIOTROPIC) RESISTANCE SELECTED BY DOXORUBICIN, IN SUBLINES OF THE HUMAN SARCOMA CELL-LINE MES-SA. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 25(MAR), 339-339.
  
• STRUCTURE-ACTIVITY OF ANTHRACYCLINES - 250-FOLD TO 1500-FOLD INCREASED POTENCY IN HUMAN-TUMORS, NON-CROSS-RESISTANCE, AND ABSENCE OF CARDIOTOXICITY IN THE CYANO-MORPHOLINO DERIVATIVE OF DOXORUBICIN Sikic, B. I., ACTON, E. M., EHSAN, M. N., Harker, W. G., Fagan, M. A., & Brown, B. W. (1984). STRUCTURE-ACTIVITY OF ANTHRACYCLINES - 250-FOLD TO 1500-FOLD INCREASED POTENCY IN HUMAN-TUMORS, NON-CROSS-RESISTANCE, AND ABSENCE OF CARDIOTOXICITY IN THE CYANO-MORPHOLINO DERIVATIVE OF DOXORUBICIN. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 25(MAR), 306-306.
  
• GASTRIN RELEASING PEPTIDE IS A SELECTIVE MITOGEN FOR SMALL CELL LUNG-CARCINOMA INVITRO Weber, S., ZUCKERMAN, J. E., Bostwick, D. G., Bensch, K. G., Sikic, B. I., & Raffin, T. A. (1984). GASTRIN RELEASING PEPTIDE IS A SELECTIVE MITOGEN FOR SMALL CELL LUNG-CARCINOMA INVITRO. CHEST, 86(2), 306-306.
  
• CHEMOTHERAPY OF SMALL-CELL CARCINOMA OF LUNG - A RANDOMIZED COMPARISON OF ALTERNATING AND SEQUENTIAL COMBINATION CHEMOTHERAPY PROGRAMS Daniels, J. R., CHAK, L. Y., Sikic, B. I., Lockbaum, P., Kohler, M., & Yu, J. (1984). CHEMOTHERAPY OF SMALL-CELL CARCINOMA OF LUNG - A RANDOMIZED COMPARISON OF ALTERNATING AND SEQUENTIAL COMBINATION CHEMOTHERAPY PROGRAMS. JOURNAL OF CLINICAL ONCOLOGY, 2(11), 1192-1199.
  
• INCREASED INCIDENCE OF ACUTE NONLYMPHOCYTIC LEUKEMIA FOLLOWING THERAPY IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG CHAK, L. Y., Sikic, B. I., TUCKER, M. A., Horns, R. C., & Cox, R. S. (1984). INCREASED INCIDENCE OF ACUTE NONLYMPHOCYTIC LEUKEMIA FOLLOWING THERAPY IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG. JOURNAL OF CLINICAL ONCOLOGY, 2(5), 385-390.
  
• CONTINUOUS INFUSION OR BOLUS INJECTION IN CANCER-CHEMOTHERAPY Carlson, R. W., & Sikic, B. I. (1983). CONTINUOUS INFUSION OR BOLUS INJECTION IN CANCER-CHEMOTHERAPY. ANNALS OF INTERNAL MEDICINE, 99(6), 823-833.
  
• COMBINATION CISPLATIN, VINBLASTINE, AND BLEOMYCIN CHEMOTHERAPY (PVB) FOR MALIGNANT GERM-CELL TUMORS OF THE OVARY Carlson, R. W., Sikic, B. I., Turbow, M. M., & Ballon, S. C. (1983). COMBINATION CISPLATIN, VINBLASTINE, AND BLEOMYCIN CHEMOTHERAPY (PVB) FOR MALIGNANT GERM-CELL TUMORS OF THE OVARY. JOURNAL OF CLINICAL ONCOLOGY, 1(10), 645-651.
  
• PULMONARY TOXICITY OF ANTITUMOR AGENTS Muggia, F. M., Louie, A. C., & Sikic, B. I. (1983). PULMONARY TOXICITY OF ANTITUMOR AGENTS. CANCER TREATMENT REVIEWS, 10(4), 221-243.
  
• DIAGNOSTIC ACCURACIES OF CLINICAL-STUDIES IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG CHAK, L. Y., PARYANI, S. B., Sikic, B. I., Lockbaum, P., Torti, F. M., & Carter, S. K. (1983). DIAGNOSTIC ACCURACIES OF CLINICAL-STUDIES IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG. JOURNAL OF CLINICAL ONCOLOGY, 1(5), 290-294.
  
• ABSORPTION OF ANTI-NEOPLASTIC DRUGS FOLLOWING LARGE-VOLUME LP ADMINISTRATION TO RATS LITTERST, C. L., Torres, I. J., Arnold, S., McGunagle, D., FURNER, R., & Guarino, A. M. (1982). ABSORPTION OF ANTI-NEOPLASTIC DRUGS FOLLOWING LARGE-VOLUME LP ADMINISTRATION TO RATS. CANCER TREATMENT REPORTS, 66(1), 147-155.
  
• HUMAN-TUMOR CLONOGENIC ASSAYS - STUDIES OF GROWTH AND DRUG SENSITIVITY Sikic, B. I., Evans, T. L., MacKintosh, F. R., & Smith, H. S. (1982). HUMAN-TUMOR CLONOGENIC ASSAYS - STUDIES OF GROWTH AND DRUG SENSITIVITY. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 23(MAR), 186-186.
  
• PATTERNS OF FAILURE IN SMALL CELL-CARCINOMA OF THE LUNG CHAK, L. Y., Daniels, J. R., Sikic, B. I., Torti, F. M., Lockbaum, P., & Carter, S. K. (1982). PATTERNS OF FAILURE IN SMALL CELL-CARCINOMA OF THE LUNG. CANCER, 50(9), 1857-1863.
  
• PULMONARY-DISEASE AS A COMPLICATION OF CHLOROZOTOCIN CHEMOTHERAPY Ahlgren, J. D., Smith, F. P., KERWIN, D. M., Sikic, B. I., Weiner, J. H., & SCHEIN, P. S. (1981). PULMONARY-DISEASE AS A COMPLICATION OF CHLOROZOTOCIN CHEMOTHERAPY. CANCER TREATMENT REPORTS, 65(3-4), 223-229.
  
• BLEOMYCIN HYDROLASE KINETICS IN THE CYTOSOL OF MALIGNANT AND NORMAL-TISSUES Sikic, B. I., & Evans, T. L. (1981). BLEOMYCIN HYDROLASE KINETICS IN THE CYTOSOL OF MALIGNANT AND NORMAL-TISSUES. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 22(MAR), 239-239.
  
• CLONAL HETEROGENEITY IN A HUMAN OVARIAN ADENOCARCINOMA MacKintosh, F. R., Louie, A. C., Evans, T. L., Amylon, M. D., & Sikic, B. I. (1981). CLONAL HETEROGENEITY IN A HUMAN OVARIAN ADENOCARCINOMA. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 22(MAR), 379-379.
  
• HUMAN-TUMOR CLONOGENIC ASSAYS - AN OVERVIEW Sikic, B. I., & Taber, R. L. (1981). HUMAN-TUMOR CLONOGENIC ASSAYS - AN OVERVIEW. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 6(3), 201-203.
  
• METHODOLOGIC PROBLEMS IN CLONOGENIC ASSAYS OF SPONTANEOUS HUMAN-TUMORS MacKintosh, F. R., Evans, T. L., & Sikic, B. I. (1981). METHODOLOGIC PROBLEMS IN CLONOGENIC ASSAYS OF SPONTANEOUS HUMAN-TUMORS. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 6(3), 205-210.
  
• RELATIVE PULMONARY TOXICITY AND ANTI-TUMOR EFFECTS OF 2 NEW BLEOMYCIN ANALOGS, PEPLEOMYCIN AND TALLYSOMYCIN-A Sikic, B. I., SIDDIK, Z. H., & Gram, T. E. (1980). RELATIVE PULMONARY TOXICITY AND ANTI-TUMOR EFFECTS OF 2 NEW BLEOMYCIN ANALOGS, PEPLEOMYCIN AND TALLYSOMYCIN-A. CANCER TREATMENT REPORTS, 64(4-5), 659-667.
  
• INTERACTION OF OTHER ANTI-CANCER DRUGS WITH BLEOMYCIN IN AN ANIMAL-MODEL OF PULMONARY TOXICITY Louie, A. C., Evans, T. L., & Sikic, B. I. (1980). INTERACTION OF OTHER ANTI-CANCER DRUGS WITH BLEOMYCIN IN AN ANIMAL-MODEL OF PULMONARY TOXICITY. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 21(MAR), 290-290.
  
• HEPATIC CYTOCHROME P-450-DEPENDENT METABOLISM AND ENZYMATIC CONJUGATION OF FOREIGN COMPOUNDS IN VITAMIN-A-DEFICIENT RATS SIDDIK, Z. H., Drew, R., LITTERST, C. L., Mimnaugh, E. G., Sikic, B. I., & Gram, T. E. (1980). HEPATIC CYTOCHROME P-450-DEPENDENT METABOLISM AND ENZYMATIC CONJUGATION OF FOREIGN COMPOUNDS IN VITAMIN-A-DEFICIENT RATS. PHARMACOLOGY, 21(6), 383-390.
  
• PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION GULLO, J. J., LITTERST, C. L., Maguire, P. J., Sikic, B. I., Hoth, D. F., & Woolley, P. V. (1980). PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 5(1), 21-26.
  
• LIPOSOMAL PROTECTION OF ADRIAMYCIN-INDUCED CARDIOTOXICITY IN MICE Rahman, A., KESSLER, A., More, N., Sikic, B., Rowden, G., & SCHEIN, P. S. (1980). LIPOSOMAL PROTECTION OF ADRIAMYCIN-INDUCED CARDIOTOXICITY IN MICE. CANCER RESEARCH, 40(5), 1532-1537.
  
• LACK OF CORRELATION BETWEEN CORTISOL-INDUCED PRECOCIOUS MATURATION OF THE FETAL RABBIT LUNG AND DRUG-METABOLISM SIDDIK, Z. H., Sikic, B. I., Drew, R., Mimnaugh, E. G., LITTERST, C. L., & Gram, T. E. (1979). LACK OF CORRELATION BETWEEN CORTISOL-INDUCED PRECOCIOUS MATURATION OF THE FETAL RABBIT LUNG AND DRUG-METABOLISM. BIOCHEMICAL PHARMACOLOGY, 28(5), 683-685.
  
• EFFECTS OF ALPHA-TOCOPHEROL ON THE TOXICITY, DISPOSITION, AND METABOLISM OF ADRIAMYCIN IN MICE Mimnaugh, E. G., SIDDIK, Z. H., Drew, R., Sikic, B. I., & Gram, T. E. (1979). EFFECTS OF ALPHA-TOCOPHEROL ON THE TOXICITY, DISPOSITION, AND METABOLISM OF ADRIAMYCIN IN MICE. TOXICOLOGY AND APPLIED PHARMACOLOGY, 49(1), 119-126.
  
• ENHANCEMENT OF BLEOMYCIN ACTIVITY AGAINST LEWIS LUNG-TUMORS IN MICE BY LOCAL HYPERTHERMIA Magin, R. L., Sikic, B. I., & Cysyk, R. L. (1979). ENHANCEMENT OF BLEOMYCIN ACTIVITY AGAINST LEWIS LUNG-TUMORS IN MICE BY LOCAL HYPERTHERMIA. CANCER RESEARCH, 39(9), 3792-3795.
  
• DISTRIBUTION OF IMIPRAMINE-C-14 IN MICE BEARING LEWIS LUNG-CARCINOMA Drew, R., Sikic, B. I., Mimnaugh, E. G., LITTERST, C. L., & Gram, T. E. (1979). DISTRIBUTION OF IMIPRAMINE-C-14 IN MICE BEARING LEWIS LUNG-CARCINOMA. LIFE SCIENCES, 25(21), 1813-1820.
  
• INVITRO DRUG-METABOLISM IN MALE AND FEMALE ATHYMIC, NUDE-MICE LITTERST, C. L., Sikic, B. I., Mimnaugh, E. G., Guarino, A. M., & Gram, T. E. (1978). INVITRO DRUG-METABOLISM IN MALE AND FEMALE ATHYMIC, NUDE-MICE. LIFE SCIENCES, 22(19), 1723-1730.
  
• EFFECT OF WHOLE-BODY HYPERTHERMIA ON DISPOSITION AND METABOLISM OF ADRIAMYCIN IN RABBITS Mimnaugh, E. G., WARING, R. W., Sikic, B. I., Magin, R. L., Drew, R., & Guarino, A. M. (1978). EFFECT OF WHOLE-BODY HYPERTHERMIA ON DISPOSITION AND METABOLISM OF ADRIAMYCIN IN RABBITS. CANCER RESEARCH, 38(5), 1420-1425.
  
• EFFECTS OF ASCORBIC-ACID DEFICIENCY AND REPLETION ON PULMONARY, RENAL, AND HEPATIC DRUG-METABOLISM IN GUINEA-PIG Sikic, B. I., Mimnaugh, E. G., LITTERST, C. L., & Gram, T. E. (1977). EFFECTS OF ASCORBIC-ACID DEFICIENCY AND REPLETION ON PULMONARY, RENAL, AND HEPATIC DRUG-METABOLISM IN GUINEA-PIG. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 179(2), 663-671.
  
• EFFECTS OF DIETARY ASCORBIC-ACID SUPPLEMENTATION ON HEPATIC DRUG-METABOLIZING-ENZYMES IN GUINEA-PIG Sikic, B. I., Mimnaugh, E. G., & Gram, T. E. (1977). EFFECTS OF DIETARY ASCORBIC-ACID SUPPLEMENTATION ON HEPATIC DRUG-METABOLIZING-ENZYMES IN GUINEA-PIG. BIOCHEMICAL PHARMACOLOGY, 26(21), 2037-2041.
  
• INTERACTION OF FLURAZEPAM WITH DIPHENYLHYDANTOIN IN RAT Sikic, B. I., & BAUMEL, I. P. (1976). INTERACTION OF FLURAZEPAM WITH DIPHENYLHYDANTOIN IN RAT. DRUG METABOLISM AND DISPOSITION, 4(6), 584-586.
  
• REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS RENAULT, P. F., Schuster, C. R., FREEDMAN, D. X., Sikic, B., NEBELDEM, D., & Halaris, A. (1974). REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS. ARCHIVES OF GENERAL PSYCHIATRY, 31(1), 95-102.
  
• EVALUATION OF A PROGRAM FOR TREATMENT OF ALCOHOLISM IN CROATIA Sikic, B. I., Walker, R. D., & PETERSON, D. R. (1972). EVALUATION OF A PROGRAM FOR TREATMENT OF ALCOHOLISM IN CROATIA. INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY, 18(3), 171-182.